Summary
The recently approved drugs for Alzheimer’s disease (AD), targeting amyloid plaques removal, only mildly slow patients’ cognitive decline as neuronal loss starts decades before plaque deposition. To delay AD onset before symptoms development, prevention of neuronal death should be prioritised instead.
An early AD pathological event is intraneuronal accumulation of amyloids (intraAβ) which can cause neuronal death at the pre-plaque stage. IntraAβ is only found in specific neuronal subtypes first to be lost in AD, suggesting it might underly their selective vulnerability. Reactive microglia could contribute to intraAβ as blocking neuroinflammatory processes in early AD reduces its accumulation. Whether microglia also contribute to intraAβ+ neurons selective loss is still unknown but could suggest repurposing of already available microglia targeting drugs for early neuroprotective therapies.
I will test this hypothesis in 5xFAD mice, first confirming intraAβ accumulates in the neuronal subtypes selectively lost, as it occurs in humans. I will analyse the contribution of reactive microglia to intraAβ neurons death by pharmaceutically rescuing their reactivity and determine if intraAβ neurons-associated microglia express AD high-risk genes, which drive late AD pathology. Because AD affects women more, possibly due to their higher inflammatory response, the sex-specificity in the previous analyses will also be tested. Finally, I will establish microglia-containing human brain organoids to recapitulate this synergy in a in vitro human AD model, providing a foundation for future drug testing.
By determining the potentially detrimental interplay between microglia reactivity and intraAβ+ neurons, using both in vivo and in vitro models, my project will lay the basis of extensive future work while defining my research niche. In the long term, my results will impact development of novel neuroprotective therapies for treating AD before neuronal loss.
An early AD pathological event is intraneuronal accumulation of amyloids (intraAβ) which can cause neuronal death at the pre-plaque stage. IntraAβ is only found in specific neuronal subtypes first to be lost in AD, suggesting it might underly their selective vulnerability. Reactive microglia could contribute to intraAβ as blocking neuroinflammatory processes in early AD reduces its accumulation. Whether microglia also contribute to intraAβ+ neurons selective loss is still unknown but could suggest repurposing of already available microglia targeting drugs for early neuroprotective therapies.
I will test this hypothesis in 5xFAD mice, first confirming intraAβ accumulates in the neuronal subtypes selectively lost, as it occurs in humans. I will analyse the contribution of reactive microglia to intraAβ neurons death by pharmaceutically rescuing their reactivity and determine if intraAβ neurons-associated microglia express AD high-risk genes, which drive late AD pathology. Because AD affects women more, possibly due to their higher inflammatory response, the sex-specificity in the previous analyses will also be tested. Finally, I will establish microglia-containing human brain organoids to recapitulate this synergy in a in vitro human AD model, providing a foundation for future drug testing.
By determining the potentially detrimental interplay between microglia reactivity and intraAβ+ neurons, using both in vivo and in vitro models, my project will lay the basis of extensive future work while defining my research niche. In the long term, my results will impact development of novel neuroprotective therapies for treating AD before neuronal loss.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101146149 |
| Start date: | 05-05-2025 |
| End date: | 04-05-2027 |
| Total budget - Public funding: | - 172 750,00 Euro |
Cordis data
Original description
The recently approved drugs for Alzheimer’s disease (AD), targeting amyloid plaques removal, only mildly slow patients’ cognitive decline as neuronal loss starts decades before plaque deposition. To delay AD onset before symptoms development, prevention of neuronal death should be prioritised instead.An early AD pathological event is intraneuronal accumulation of amyloids (intraAβ) which can cause neuronal death at the pre-plaque stage. IntraAβ is only found in specific neuronal subtypes first to be lost in AD, suggesting it might underly their selective vulnerability. Reactive microglia could contribute to intraAβ as blocking neuroinflammatory processes in early AD reduces its accumulation. Whether microglia also contribute to intraAβ+ neurons selective loss is still unknown but could suggest repurposing of already available microglia targeting drugs for early neuroprotective therapies.
I will test this hypothesis in 5xFAD mice, first confirming intraAβ accumulates in the neuronal subtypes selectively lost, as it occurs in humans. I will analyse the contribution of reactive microglia to intraAβ neurons death by pharmaceutically rescuing their reactivity and determine if intraAβ neurons-associated microglia express AD high-risk genes, which drive late AD pathology. Because AD affects women more, possibly due to their higher inflammatory response, the sex-specificity in the previous analyses will also be tested. Finally, I will establish microglia-containing human brain organoids to recapitulate this synergy in a in vitro human AD model, providing a foundation for future drug testing.
By determining the potentially detrimental interplay between microglia reactivity and intraAβ+ neurons, using both in vivo and in vitro models, my project will lay the basis of extensive future work while defining my research niche. In the long term, my results will impact development of novel neuroprotective therapies for treating AD before neuronal loss.
Status
SIGNEDCall topic
HORIZON-MSCA-2023-PF-01-01Update Date
22-11-2024
Images
No images available.
Geographical location(s)
